Telephone-Based Weight Loss Intervention Successful in Breast Cancer Survivors
Results of the Breast Cancer Weight Loss trial were presented at the 2023 ASCO Annual Meeting.
Results of the Breast Cancer Weight Loss trial were presented at the 2023 ASCO Annual Meeting.
Patients with HR+, HER2- metastatic breast cancer whose disease progressed on endocrine therapy (ET) and a CDK4/6 inhibitor have better progression-free survival if they switch ET and receive ribociclib than if they switch ET alone, a phase 2 study suggests.
Extended antibiotics do not reduce infection or reconstruction failure after postmastectomy breast reconstruction.
Routine testing for ESR1 mutations should occur upon recurrence or progression of HR+, HER2- metastatic breast cancer, a guideline suggests.
Cancer death rates in the US have declined in recent years, but the declines vary by congressional district, a study suggests.
This review of the options and challenges facing patients with breast cancer reviews the complications that increase patients’ risk for reconstructive burnout.
In draft recommendation, task force says evidence is insufficient for assessing benefits and harms of mammography for those aged 75 years and older, women with dense breasts.
Women with higher-than-average breast cancer risk, especially Black and Ashkenazi Jewish women, should start screening at younger age.
Researchers sought to determine if a cardiotoxicity management strategy could allow women with HER2-positive breast cancer to complete trastuzumab therapy.
US counties with food deserts or food swamps tend to have higher rates of death from obesity-related cancers, a study suggests.